LVOT obstruction is a serious complication of TMVR. BATMAN may help protect patients from LVOT obstruction without leading to any additional risks.

Kenneth Bilchick, MD, spoke to Cardiovascular Business about new data he presented at Heart Rhythm 2026. 

TAVR procedures with a higher implant depth are associated with certain clinical benefits after one year, according to a new study of data from more than 600 patients.

The FDA has identified another safety concern with Johnson & Johnson MedTech's Automated Impella Controllers. This comes after the devices were linked to five separate recalls in 2025. 

The Alliance for Aging Research wants CMS to go through with policy changes that could make many more patients eligible for TAVR. The agency is currently considering the changes, and a final decision is expected in June. 

This Class II recall includes more than 18,000 cannulae used during cardiac surgery.

"Pulmonary embolism is fundamentally a cardiovascular disease, where restoration of hemodynamic stability, beyond simple clot removal, is the key determinant of patient recovery,” one researcher explained. 

The purchase price could end up being closer to $200 million if certain commercial milestones are met.

Ziad Ali, MD, said the new device has completely changed the way he and his colleagues treat patients with calcified coronary artery disease. 

These three-year data represent a major update to one of the more noteworthy TAVR trials in recent memory.